Real-World data on the first UK Series of MINIject supraciliary implant with six months follow up

Abstract Purpose:This study evaluates the efficacy and safety of the MINIject (iStar Medical, Wavre, Belgium) supraciliary implant. Methods:Patients with medically uncontrolled primary open angle glaucoma, primary angle closure glaucoma and normal tension glaucoma. This first in the UK, restrospective, single-centre, interventional study evaluated the implantation of the MINIject in 45 eyes, including 11 standalone cases and 34 cases combined with phacoemulsification. Primary outcome was reduction of intraocular pressure (IOP) at 6 months. Secondary outcomes included success defined as IOP of ≤21 mmHg and >5 mmHg with an IOP reduction of ≥20% without (complete success) or with (qualified success) the use of glaucoma medications, reduction of IOP and glaucoma medications during follow-up and adverse events. Results:Mean (±SD) baseline IOP was 19.02±5.11 mmHg on 2.22±1.04 medications. At 6 months, 71.1% (n=32) achieved ≥20% IOP reduction with 91% (n=41) of patients being drop-independent. The mean IOP was 13.02±4.74 mmHg (range 4-29 mmHg) with the average percentage decrease being 31.55%. Furthermore, 71.1% (n=32) of eyes achieved an IOP of <15 mmHg. Mean IOP at 6 months in the phaco-combined group was 13.06 mmHg and in the standalone group was 12.91 mmHg. The reduction in IOP in these subgroups was 5.80 mmHg and 6.64 mmHg respectively (p=0.74). At 6 months, 66.67% of patients met the criteria for complete success and 71.11% for qualified success. Adverse events occured in 15.6% (n=7) of eyes. No sight-threatening events occurred. Conclusion:This study shows promising IOP-lowering results and medication reduction over 6 months with few adverse events.